Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standardization of D. pteronyssinus Allergen Extract (HEP Units)
NCT01821716Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Mar 2013
- Primary completion
- Jan 2014
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of dermatophagoides pteronyssinus in allergic rhinitis (AR), allergic asthma, house dust mite allergy, sponsored by LETI Pharma. Started Mar 2013; status: completed.
02
Drugs
dermatophagoides pteronyssinus
03
Conditions
allergic rhinitis (AR)allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on NCT01821716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01821716.